Physician profile
Susan Azad
NPI 1437207073
$2,147.10
in general payments reported to CMS, 2019-2025
22 companies · $850 in 2025
The $850 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $61.77 · 2021: $106 · 2022: $323 · 2023: $127 · 2024: $406 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $287.44 | 2024-2025 | Repatha, Otezla, Tezspire |
| Biohaven Pharmaceutical Holding Company LTD. | $279.49 | 2022 | |
| Abbvie INC. | $242.89 | 2021-2025 | |
| Pfizer INC. | $226.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.70 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $170.03 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Nevro Corp. | $123.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.73 | 2025 | |
| Exact Sciences Corporation | $109.23 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $71.67 | 2023-2025 | Trintellix |
| Novo Nordisk INC | $62.33 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $46.93 | 2025 | Fasenra |
| Lilly USA, LLC | $33.49 | 2019-2025 | Zepbound, Mounjaro |
| Mallinckrodt Enterprises LLC | $32.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $24.64 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $24.13 | 2025 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.39 | 2020 | |
| Philips North America LLC | $19.44 | 2025 | Vest Therapy Und |
| Heartflow, INC. | $19.01 | 2025 | |
| Currax Pharmaceuticals LLC | $15.01 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.